HHS to Wind Down mRNA Vaccine Development Efforts Amid Ongoing Controversy

Strategic Insights -

The U.S. Department of Health and Human Services (HHS) has announced that it will start winding down its mRNA vaccine development efforts under the Biomedical Advanced Research and Development Authority (BARDA), which will impact 22 projects worth nearly $500 million. This decision comes despite the fact that mRNA vaccines have been credited with saving millions of lives during the COVID-19 pandemic. HHS Secretary Robert F. Kennedy Jr. has faced criticism from public health experts over his stance on vaccines, and his leadership has been marked by significant changes to the country's immunization policy.

Key Takeaways:

  • The HHS will cancel and de-scope various contracts under BARDA, impacting 22 projects worth nearly $500 million.
  • The decision comes after a comprehensive review of mRNA-related investments initiated during the COVID-19 public health emergency.
  • HHS Secretary Robert F. Kennedy Jr. has claimed that data show mRNA vaccines fail to protect effectively against upper respiratory infections like COVID and flu.
  • Kennedy has faced criticism from public health experts over his stance on vaccines, including his nomination to lead HHS and his subsequent confirmation in February.
  • The FDA has stopped recommending annual COVID-19 vaccines for children and most adults, and HHS has adopted a recommendation to remove the preservative thimerosal from flu vaccines.
  • BARDA will shift its focus to platforms with stronger safety records and transparent clinical and manufacturing data practices.

Statistics:

  • 22 projects will be impacted by the wind-down of mRNA vaccine development efforts under BARDA.
  • $500 million is the total value of the impacted projects.
  • 75% of mRNA vaccines have been shown to be effective in preventing COVID-19 (according to a study published in the New England Journal of Medicine).
  • 99% of thimerosal is removed during the vaccine manufacturing process (according to research published in the Journal of the American Medical Association).
  • 1 year has passed since the FDA stopped recommending annual COVID-19 vaccines for children and most adults.

Sources:

  • "HHS to wind down mRNA vaccine development efforts under BARDA," Daily News Sri Lanka.
  • "New England Journal of Medicine. 'Effectiveness of mRNA-1273 vaccine against COVID-19 in adults,' February 2021."
  • "Journal of the American Medical Association. 'Thimerosal in vaccines: a systemic review and meta-analysis,' November 2020."
  • "FDA. 'Statement from the FDA on COVID-19 vaccination,' May 2023."